NASDAQ:DBVT

Dbv Technologies S.a Stock Insider Trading

Healthcare > Biotechnology

Buy DBVT

*Your capital is at risk

$15.82

+0.0900 (+0.572%)

At Close: Jul 02, 2026

DBV Technologies S.A Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.08. In total, the insiders bought 196.5M and sold 3.4M DBVT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	88.08
● Buy	196.5M shares
● Sell	3.4M shares
72% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Jun 08, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 88.08. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 07, 2025 Buy	Warrants (right to buy)	Bpifrance Sa 10 Percent Owner	10% Owner	6 556 781 Value: $48.8M
Mar 27, 2025 Buy	Ordinary Shares	Epic Bpifrance Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Epic Bpifrance Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Epic Bpifrance Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Epic Bpifrance Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Investissement S.a.s. Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Investissement S.a.s. Member Of 10% Owner Group	Other	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Sa 10 Percent Owner	10% Owner	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Sa 10 Percent Owner	10% Owner	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Sa 10 Percent Owner	10% Owner	0 Value: $0
Mar 27, 2025 Buy	Ordinary Shares	Bpifrance Sa 10 Percent Owner	10% Owner	0 Value: $0
Mar 27, 2025 Buy	BS Warrant A-Award	Baker Bros. Advisors Lp	Director	25 005 240 Value: $97.8M
Mar 27, 2025 Buy	BS Warrant A-Award	Baker Bros. Advisors Lp	Director	25 005 240 Value: $97.8M
Mar 27, 2025 Buy	First Pre-Funded Warrant A-Award	Baker Bros. Advisors Lp	Director	25 005 240 Value: $97.8M
Mar 27, 2025 Buy	BS Warrant A-Award	Baker Bros. Advisors Lp	Director	2 299 656 Value: $8.99M
Mar 27, 2025 Buy	First Pre-Funded Warrant A-Award	Baker Bros. Advisors Lp	Director	2 299 656 Value: $8.99M
Mar 27, 2025 Buy	First Pre-Funded Warrant A-Award	Baker Bros. Advisors Lp	Director	2 299 656 Value: $8.99M
Mar 27, 2025 Buy	BS Warrant A-Award	Baker Bros. Advisors Lp	Director	2 299 656 Value: $8.99M
Mar 27, 2025 Buy	First Pre-Funded Warrant A-Award	Baker Bros. Advisors Lp	Director	25 005 240 Value: $97.8M
Jan 30, 2025 Sell	Ordinary Shares S-Sale	Mohideen Pharis Chief Medical Officer	Officer	600 Value: $510
Jan 30, 2025 Sell	Ordinary Shares S-Sale	Mohideen Pharis Chief Medical Officer	Officer	600 Value: $510
Dec 04, 2024 Buy	Employee Stock Option (right to buy) A-Award	Tasse Daniel Chief Executive Officer	CEO / President	813 200 Value: $723.7K
Dec 04, 2024 Buy	Employee Stock Option (right to buy) A-Award	Tasse Daniel Chief Executive Officer	CEO / President	813 200 Value: $723.7K
Nov 25, 2024 Sell	Ordinary Shares S-Sale	Mohideen Pharis Chief Medical Officer	Officer	565 Value: $322
Nov 25, 2024 Sell	Ordinary Shares S-Sale	Mohideen Pharis Chief Medical Officer	Officer	565 Value: $322

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DBV TECHNOLOGIES S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical t...

Read Full Profile Here